18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms

Zhejiang University

Status: Not yet enrolling

Conditions: Neuroendocrine Tumors

Treatments: Diagnostic Test: 18F-AlF-NOTA-Octreotide PET-CT or PET-MR

Study type: Observational

Funder types: Other

Identifiers

NCT07102056

FirstZhejiangU-18OC-NENs

Details and patient eligibility

About

The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.

Enrollment: 152 estimated patients

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Clinical diagnosed of neuroendocrine neoplasms.
2. Suspected of neuroendocrine neoplasms.

Exclusion criteria

1. Inability to undergo biopsy/surgical treatment.
2. Concurrent active malignancy.
3. Severe uncontrolled comorbidities/active infections.
4. Inability to provide informed consent.

Trial design